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The potential use of stem cells for cell-based tissue
repair and regeneration offers alternative therapeutic
strategies for various diseases. Adipose-derived stem
cells (ADSCs) have emerged as a promising source of
stem cells suitable for transplantation in regenerative
medicine and wound repair. A recent publication in
Stem Cell Research & Therapy by Zhang and colleagues
reports a new finding about the anti-fibrosis role of
ADSCs and conditioned media derived from them on
hypertrophic scar formation in vivo.wound repair and cell-based therapy in regenerativeCommentary
Recent developments in defining the roles played by
stem cells may lead to tissue repair therapies and even
the eventual replacement of organs. To be used in trans-
plantation therapy, stem cells should be easily available
in abundant quantities and have the potential to differ-
entiate into multiple lineages in a reproducible manner.
This commentary discusses the findings from Zhang
and colleagues published in a recent article in Stem Cell
Research & Therapy revealing the anti-scarring role of
adipose-derived stem cells (ADSCs) and conditioned
media derived from them (ADSC-CM) [1]. Wound heal-
ing is a complex process of repair and regeneration that
involves the coordinated efforts of complex biological pro-
cesses such as inflammation, proliferation and regener-
ation [2]. Stem cells, including embryonic stem cells
(ESCs), induced pluripotent stem cells (iPSCs) and adult
stem cells, have the capacity to proliferate and self-renew
and can be differentiated into multiple lineage types [3].* Correspondence: manoj.gupta@joslin.harvard.edu
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from most somatic cell types after reprogramming [4].
Both of these pluripotent cell types offer enormous poten-
tial for disease modeling, drug testing and transplantation,
although they are still associated with some limitations,
such as immunocombatibility and teratoma formation [5].
In contrast, adult stem cells, including ADSCs, are
immunocompatible and without teratogenic properties.
ADSCs, multipotent stem cells, are easily derived from
various adipose tissues [6]. The differentiation potential
and proliferation capacity of ADSCs and soluble factors
from them offer tremendous therapeutic potential for
medicine [7, 8]. The efficacy and safety of ADSCs have
been determined in several preclinical and clinical stud-
ies [9]. A lot of progress has been made in characterizing
and identifying specific cell-surface markers of ADSCs
from subcutaneous and visceral fat depots [10, 11].
ADSCs are autologous, non-immunogenic, and easily
available in large quantities, and seem to be a promising
approach for wound repair and anti-scar therapy (Fig. 1).
In a recent publication, Zhang and colleagues used ADSCs
as an anti-fibrosis agent in a rabbit ear hypertrophic scar-
ring model [1]. To this end, the authors derived ADSCs
positive for CD73, CD90 and CD105 from groin fat pads
of rabbit and used them to reduce scar hypertrophy in the
ear scarring model in rabbit. Using ultrasonography and
hematoxylin and eosin staining, they found that the scar
elevation index was significantly decreased in scars treated
with ADSCs and ADSC-CM. Also, collagen fibers were
regularly arranged in the ADSC-treated groups compared
with control groups. These findings were confirmed by
real time PCR—lower expression of collagen type 1 and
alpha smooth muscle actin in ADSC- and ADSC-CM-
treated scars—proving that these adult stem cells have
anti-fibrosis characteristics. In this elegant study, theticle is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Adipose-derived stem cells (ADSCs) reduce hypertrophic
scarring in a rabbit ear model
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the scar tissue even after 3 weeks of initial treatment, indi-
cating the active involvement of ADSCs in wound repair.
However, they were not able to determine the survival rate
of the ADSCs due to only temporary labeling with the
dye. Therefore, lineage tracing until the end-point will be
essential in any such future studies, which is the only way
to discriminate between tissue regeneration in situ and
stem cell-based wound healing.
Zhang and colleagues’ study not only characterized the
ADSCs by surface markers, but also demonstrated the
successful trans-differentiation of ADSCs into adipocytes
and osteocytes, confirmed by using oil red O staining
and alizarin red S. Their work is also well supported by
a similar study in which the authors demonstrated that
bone marrow-derived mesenchymal stem cells played
important roles in wound repair and tissue remodeling
dependent on p53 using the same hypertrophic scarring
model in rabbit [12].
Conclusion
Zhang and colleagues’ study is impressive, showing the
anti-scarring effect of ADSCs and raising several ques-
tions for future investigations (Fig. 1). What are the key
transcriptional factors and molecular pathways initially
involved in lineage-specific differentiation of ADSCs?
What role do these cells have as precursors of various
somatic cell types, including fibroblasts and endothelial
cells? Are ADSCs safe to use as an anti-fibrosis agent?
What is the survival rate of these stem cells during
transplantation? And, most importantly, how dependent
is ADSC differentiation potential on their site of origin
and the donor’s age and gender? These are a few of the
myriad questions remaining to be answered regardingthe use of ADSCs in wound repair and transplantation
therapies. Answers to these questions may help to define
strategies for the treatment of wounds in patients with
various disease backgrounds, such as diabetes, sclero-
derma, burns, and epidermolysis bullosa hereditaria.
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